UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 18, 2006
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 1.01. ENTRY INTO A MATERIAL DEFINITVE AGREEMENT.
On September 18, 2006, the Compensation Committee of Integra LifeSciences
Holdings Corporation (the "Company") set the performance goals for determining
awards payable (the "Performance Goals") under the Integra LifeSciences Holdings
Corporation Management Incentive Compensation Plan (the "Plan") to David B.
Holtz and Judith O'Grady, the Company's executive officers who participate in
the Plan, for the performance period of July 1, 2006 to December 31, 2006 (the
"Performance Period").
The Performance Goals are based on the attainment of a specific level of
Adjusted EBITDA performance by the Company during performance period. The target
award for Mr. Holtz and Ms. O'Grady is 16.25% of their annual base salary. The
amount of the award may be increased as much as 50% above the target award based
on the extent to which the level of achievement of the Performance Goals exceeds
the target level for the Performance Period.
A description of the Plan is contained in Item 1.01 of the Company's Current
Report on Form 8-K filed with the Securities and Exchange Commission on August
4, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: September 22, 2006 By: /s/ Stuart M. Essig
-----------------------------
Stuart M. Essig
President and Chief Executive Officer